Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) is a housekeeping enzyme that plays a central role in the purine salvage pathway. It catalyzes the conversion of hypoxanthine to inosine monophosphate (IMP) and guanine to guanosine monophosphate (GMP), using 5-phosphoribosyl 1-pyrophosphate (PRPP) as a co-substrate. Deficiency or mutations in HPRT cause Lesch-Nyhan syndrome, a rare X-linked recessive disorder characterized by uric acid overproduction and severe neurological symptoms.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hypoxanthine-Guanine Phosphoribosyltransferase (HPRT).